Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
2024. 11. 04. 21:00:00
|
Vált.
+20,0000
|
Forgalom (db) |
Vétel2024. 11. 04. |
Eladás2024. 11. 04. |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
|
11 042,0000GBX
|
+0,18%
|
1,3 mill.
Forgalom(GBP): 143,72 mill. |
10 900,0000Vétel (db): 30 |
11 900,0000Eladás (db): 200 |
171,65 mrd.GBP |
- |
- |
Cégbemutató
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Igazgatóság & Felügyelőbizottság
| CEO |
| Pascal Soriot |
| Igazgatóság |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Felügyelőbizottság |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |
